l -2-Hydroxyglutarate: An Epigenetic Modifier and Putative Oncometabolite in Renal Cancer

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154

Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases

Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.-H., Ito, S., Yang, C., Wang, P., Xiao, M.-T., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.12.014 · Cited by 2,875

Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation

Figueroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H. F., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.015 · Cited by 2,766

Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression

Sreekumar, A., Poisson, L., Rajendiran, T. M., Khan, A. P., Cao, Q., Yu, J., Laxman, B., Mehra, R., Lonigro, R. J., Li, Y., et al. (2009) · Nature · doi:10.1038/nature07762 · Cited by 2,269

The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate

Ward, P. S., Patel, J., Wise, D. R., Abdel-Wahab, O., Bennett, B. D., Coller, H. A., Cross, J. R., Fantin, V. R., Hedvat, C. V., Perl, A. E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.01.020 · Cited by 2,020

Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia

Metallo, C. M., Gameiro, P. A., Bell, E. L., Mattaini, K. R., Yang, J., Hiller, K., Jewell, C. M., Johnson, Z. R., Irvine, D. J., Guarente, L., et al. (2012) · Nature · doi:10.1038/nature10602 · Cited by 1,791

Mutation in TET2 in Myeloid Cancers

Delhommeau, F., Dupont, S., Valle, V. D., James, C., Trannoy, S., Massé, A., Kosmider, O., Le Couedic, J.-P., Robert, F., Alberdi, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810069 · Cited by 1,776

Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer

The Multiple Leiomyoma Consortium (2002) · Nature Genetics · doi:10.1038/ng849 · Cited by 1,635

Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2

Ko, M., Huang, Y., Jankowska, A. M., Pape, U. J., Tahiliani, M., Bandukwala, H. S., An, J., Lamperti, E. D., Koh, K. P., Ganetzky, R. D., et al. (2010) · Nature · doi:10.1038/nature09586 · Cited by 1,340

Integrated molecular analysis of clear-cell renal cell carcinoma

Sato, Y., Yoshizato, T., Shiraishi, Y., Maekawa, S., Okuno, Y., Kamura, T., Shimamura, T., Sato‐Otsubo, A., Nagae, G., Suzuki, H., et al. (2013) · Nature Genetics · doi:10.1038/ng.2699 · Cited by 1,257

The cpk model of recessive PKD shows glutamine dependence associated with the production of the oncometabolite 2-hydroxyglutarate

Hwang, V. J., Kim, J., Rand, A. A., Yang, C., Sturdivant, S., Hammock, B. D., Bell, P. D., Guay‐Woodford, L. M., & Weiss, R. H. (2015) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00238.2015 · Cited by 43

Metabolic Signaling to Epigenetic Alterations in Cancer

Kim, J., & Yeom, Y. I. (2017) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2017.185 · Cited by 45

Integrative cross-platform analyses identify enhanced heterotrophy as a metabolic hallmark in glioblastoma

Prabhu, A. H., Kant, S., Kesarwani, P., Ahmed, K. A., Forsyth, P. A., Nakano, I., & Chinnaiyan, P. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy185 · Cited by 38

L2hgdh Deficiency Accumulates l -2-Hydroxyglutarate with Progressive Leukoencephalopathy and Neurodegeneration

Ma, S., Sun, R., Jiang, B., Gao, J., Deng, W., Liu, P., He, R., Cui, J., Ji, M., Yi, W., et al. (2017) · Molecular and Cellular Biology · doi:10.1128/mcb.00492-16 · Cited by 39

Epigenetic Reprogramming of CD4+ Helper T Cells as a Strategy to Improve Anticancer Immunotherapy

Renaude, E., Kroemer, M., Borg, C., Peixoto, P., Hervouet, É., Loyon, R., & Adotévi, O. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.669992 · Cited by 40

Lactate Dehydrogenase C Produces S-2-Hydroxyglutarate in Mouse Testis

Teng, X., Emmett, M. J., Lazar, M. A., Goldberg, E., & Rabinowitz, J. D. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00290 · Cited by 39

Quantitation of isocitrate dehydrogenase (IDH)-induced D and L enantiomers of 2-hydroxyglutaric acid in biological fluids by a fully validated liquid tandem mass spectrometry method, suitable for clinical applications

Poinsignon, V., Mercier, L., Nakabayashi, K., David, M. D., Lalli, A., Penard‐Lacronique, V., Quivoron, C., Saada, V., de Botton, S., Broutin, S., et al. (2016) · Journal of Chromatography B · doi:10.1016/j.jchromb.2016.04.030 · Cited by 43

An l-2-hydroxyglutarate biosensor based on specific transcriptional regulator LhgR

Kang, Z., Zhang, M., Gao, K., Zhang, W., Meng, W., Liu, Y., Xiao, D., Guo, S., Ma, C., Gao, C., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23723-7 · Cited by 41

Renal cell carcinoma: a critical analysis of metabolomic biomarkers emerging from current model systems

Rodrigues, D., Monteiro, M. S., Jerónimo, C., Henrique, R., Belo, L., Bastos, M. D. L., de Pinho, P. G., & Carvalho, M. C. (2016) · Translational research · doi:10.1016/j.trsl.2016.07.018 · Cited by 38

Tissue-Based Metabolomics to Analyze the Breast Cancer Metabolome

Budczies, J., & Denkert, C. (2016) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-319-42118-6_7 · Cited by 39

The transcription factors aryl hydrocarbon receptor and MYC cooperate in the regulation of cellular metabolism

Lafita‐Navarro, M. C., Perez‐Castro, L., Zacharias, L. G., Barnes, S. D., DeBerardinis, R. J., & Conacci‐Sorrell, M. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ac120.014189 · Cited by 37

TCA cycle-derived oncometabolites in cancer and the immune microenvironment

Sarkar, S., Chang, C.-I., Jean, J., & Wu, M. (2025) · Journal of Biomedical Science · doi:10.1186/s12929-025-01186-y · Cited by 39

Mitochondria and CancerPreprint

Kenny, T. C., & Birsoy, K. (2024) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041534 · Cited by 40

Metabolomic and elemental profiling of human tissue in kidney cancer

Nizioł, J., Copié, V., Tripet, B., Nogueira, L. B., Nogueira, K. D. O. P. C., Ossoliński, K., Arendowski, A., & Ruman, T. (2021) · Metabolomics · doi:10.1007/s11306-021-01779-2 · Cited by 33

Deciphering the Warburg Effect: Metabolic Reprogramming, Epigenetic Remodeling, and Cell Dedifferentiation

Li, A. M., & Ye, J. (2023) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-062822-120857 · Cited by 31

Metabostemness: Metaboloepigenetic reprogramming of cancer stem-cell functions

Menéndez, J. A., Corominas-Faja, B., Cuyàs, E., & Alarcón, T. (2014) · Oncoscience · doi:10.18632/oncoscience.113 · Cited by 32

Metabo-Devo: A metabolic perspective of development

Gándara, L., & Wappner, P. (2018) · Mechanisms of Development · doi:10.1016/j.mod.2018.02.004 · Cited by 31

Intergenerational trauma transmission is associated with brain metabotranscriptome remodeling and mitochondrial dysfunction

Alhassen, S., Chen, S., Alhassen, L., Phan, A., Khoudari, M., Silva, A. D., Barhoosh, H., Wang, Z., Parrocha, C. M. T., Shapiro, E., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-02255-2 · Cited by 37

Metabolomics in Cancer Biomarker Research

Wang, X., Chen, S., & Jia, W. P. (2016) · Current Pharmacology Reports · doi:10.1007/s40495-016-0074-x · Cited by 35

Oncometabolite L‐2‐hydroxyglurate directly induces vasculogenic mimicry through PHLDB2 in renal cell carcinoma

Wang, H., Wang, L., Zheng, Q., Lu, Z., Chen, Y., Shen, D., Xue, D., Jiang, M., Ding, L., Zhang, J., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.33435 · Cited by 32

Metabolic Fuel for Epigenetic: Nuclear Production Meets Local Consumption

Boon, R. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.768996 · Cited by 35

Cancer metabolomics in basic science perspective

Kwon, H. N., Oh, S., Jin, X., An, Y., & Park, S. (2015) · Archives of Pharmacal Research · doi:10.1007/s12272-015-0552-4 · Cited by 32

Enigmas of IDH mutations in hematology/oncology

Heuser, M., Cruz, M. M. A., Goparaju, R., & Chaturvedi, A. (2015) · Experimental Hematology · doi:10.1016/j.exphem.2015.05.005 · Cited by 28

MYC Regulation of D2HGDH and L2HGDH Influences the Epigenome and Epitranscriptome

Qiu, Z., Lin, A., Jiang, S., Elkashef, S. M., Myers, J., Srikantan, S., Sasi, B. K., Cao, J. Z., Godley, L. A., Rakheja, D., et al. (2020) · Cell chemical biology · doi:10.1016/j.chembiol.2020.02.002 · Cited by 31

GABPA-activated TGFBR2 transcription inhibits aggressiveness but is epigenetically erased by oncometabolites in renal cell carcinoma

Fang, Z., Zhang, N., Yuan, X., Xing, X., Li, X., Qin, X., Liu, Z., Neo, S., Liu, C., Kong, F., et al. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02382-6 · Cited by 28

Regulation of Glutarate Catabolism by GntR Family Regulator CsiR and LysR Family Regulator GcdR in Pseudomonas putida KT2440

Zhang, M., Kang, Z., Guo, X., Guo, S., Xiao, D., Liu, Y., Ma, C., Xu, P., & Gao, C. (2019) · mBio · doi:10.1128/mbio.01570-19 · Cited by 28

Oncometabolites in cancer: from cancer cells to the tumor microenvironment

Chen, L., & Huang, M. (2024) · Holistic Integrative Oncology · doi:10.1007/s44178-024-00096-7 · Cited by 28

D-2-Hydroxyglutarate and L-2-Hydroxyglutarate Inhibit IL-12 Secretion by Human Monocyte-Derived Dendritic Cells

Ugele, I., Cárdenas-Conejo, Z. E., Hammon, K., Wehrstein, M., Bruß, C., Peter, K., Singer, K., Gottfried, E., Boesch, J., Oefner, P. J., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030742 · Cited by 32

The Complex Interplay between Metabolic Reprogramming and Epigenetic Alterations in Renal Cell Carcinoma

Lameirinhas, A., Miranda‐Gonçalves, V., Henrique, R., & Jerónimo, C. (2019) · Genes · doi:10.3390/genes10040264 · Cited by 28

Indirect Enantioseparations: Recent Advances in Chiral Metabolomics for Biomedical Research

Bogos, L.-G., Pralea, I.-E., Moldovan, R.-C., & Iuga, C. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137428 · Cited by 27

A Drosophila model of combined D-2- and L-2-hydroxyglutaric aciduria reveals a mechanism linking mitochondrial citrate export with oncometabolite accumulation

Li, H., Hurlburt, A. J., & Tennessen, J. M. (2018) · Disease Models & Mechanisms · doi:10.1242/dmm.035337 · Cited by 27

The role of diet in renal cell carcinoma incidence: an umbrella review of meta-analyses of observational studies

Liao, Z., Fang, Z., Gou, S., Luo, Y., Liu, Y., He, Z., Li, X., Peng, Y., Fu, Z., Li, D., et al. (2022) · BMC Medicine · doi:10.1186/s12916-021-02229-5 · Cited by 27

Cancer plasticity: Investigating the causes for this agility

Saha, S., Pradhan, N., Neha, B., Mahadevappa, R., Minocha, S., & Kumar, S. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.12.005 · Cited by 27

Metabolic Reprogramming and Redox Signaling in Pulmonary Hypertension

Plecitá‐Hlavatá, L., D’Alessandro, A., Kasmi, K. E., Li, M., Zhang, H., Ježek, P., & Stenmark, K. R. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-63245-2_14 · Cited by 26

Aspirin Reduces Plasma Concentrations of the Oncometabolite 2-Hydroxyglutarate: Results of a Randomized, Double-Blind, Crossover Trial

Liesenfeld, D. B., Botma, A., Habermann, N., Tóth, R., Weigel, C., Popanda, O., Klika, K. D., Potter, J. D., Lampe, J. W., & Ulrich, C. M. (2016) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-15-0697 · Cited by 24

Characterization of cancer-associated IDH2 mutations that differ in tumorigenicity, chemosensitivity and 2-hydroxyglutarate production

Kotredes, K. P., Razmpour, R., Lutton, E. M., Alfonso‐Prieto, M., Ramirez, S. H., & Gamero, A. M. (2019) · Oncotarget · doi:10.18632/oncotarget.26848 · Cited by 24

The prowess of metabolomics in cancer research: current trends, challenges and future perspectives

Taunk, K., Jajula, S., Bhavsar, P. P., Choudhari, M., Bhanuse, S. G., Tamhankar, A. S., Naiya, T., Kalita, B., & Rapole, S. (2024) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-024-05041-w · Cited by 24

Glucose metabolism and its direct action in cancer and immune regulation: opportunities and challenges for metabolic targeting

Pan, B., Hsu, C.-C., Wu, H., Chen, Y.-R., Zhou, X., Wang, S., Li, C., & Lin, H.-K. (2025) · Journal of Biomedical Science · doi:10.1186/s12929-025-01167-1 · Cited by 27

Untangling the Metabolic Reprogramming in Brain Cancer: Discovering Key Molecular Players Using Mass Spectrometry

Sorokin, A., Shurkhay, V. A., Игоревич, П. С., Zhvansky, E. S., Ivanov, D. G., Kulikov, E. E., Popov, I. A., Aa, P., & Николаев, Е. Н. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190729154543 · Cited by 24

5‑Hydroxymethylcytosine as a potential epigenetic biomarker in papillary thyroid carcinoma

Tong, M., Gao, S., Qi, W., Chang, S., Qiu, M., Yang, F. W., Bai, S., Li, H., Wang, Z., Sun, Z., et al. (2019) · Oncology Letters · doi:10.3892/ol.2019.10531 · Cited by 24

Coalescing lessons from oxygen sensing, tumor metabolism, and epigenetics to target VHL loss in kidney cancer

Chakraborty, A. A. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.03.012 · Cited by 22

Role of metabolomics-derived biomarkers to identify renal cell carcinoma: a comprehensive perspective of the past ten years and advancements

Gupta, A. K., Nath, K., Bansal, N., & Kumar, M. (2019) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2020.1704259 · Cited by 21

Bioenergetic Profiling of the Differentiating Human MDS Myeloid Lineage with Low and High Bone Marrow Blast Counts

Poulaki, A., Κάτσιλα, Θ., Stergiou, I. Ε., Giannouli, S., Gómez-Tamayo, J. C., Piperaki, E., Kambas, K., Dimitrakopoulou, A., Patrinos, G. P., Tzioufas, A. G., et al. (2020) · Cancers · doi:10.3390/cancers12123520 · Cited by 21

L-2hydroxyglutaric acid rewires amino acid metabolism in colorectal cancer via the mTOR-ATF4 axis

Tabata, S., Kojima, Y., Sakamoto, T., Igarashi, K., Umetsu, K., Ishikawa, T., Hirayama, A., Kajino‐Sakamoto, R., Sakamoto, N., Yasumoto, K., et al. (2023) · Oncogene · doi:10.1038/s41388-023-02632-7 · Cited by 24

Metabolomics informs common patterns of molecular dysfunction across histologies of renal cell carcinoma

DiNatale, R. G., Sánchez, A., Hakimi, A. A., & Reznik, E. (2019) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2019.04.028 · Cited by 20

Epigenome modifiers and metabolic rewiring: New frontiers in therapeutics

Ferrari, A., Longo, R., Silva, R., Mitro, N., Caruso, D., De Fabiani, E., & Crestani, M. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.08.008 · Cited by 19

The immunometabolite S-2-hydroxyglutarate exacerbates perioperative ischemic brain injury and cognitive dysfunction by enhancing CD8+ T lymphocyte-mediated neurotoxicity

Faqiang, Z., Niu, M., Guo, K.-K., Ma, Y., Fu, Q., Liu, Y., Feng, Z., Mi, W., & Wang, L. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02537-4 · Cited by 20

The two enantiomers of 2-hydroxyglutarate differentially regulate cytotoxic T cell function

Foskolou, I. P., Cunha, P. P., Sánchez‐López, E., Minogue, E., Nicolet, B. P., Guislain, A., Jorgensen, C., Kostidis, S., Zandhuis, N. D., Barbieri, L., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113013 · Cited by 19

Metabolite profiling of human renal cell carcinoma reveals tissue-origin dominance in nutrient availability

Abbott, K. L., Ali, A., Reinfeld, B. I., Deik, A., Subudhi, S., Landis, M. D., Hongo, R. A., Young, K. L., Kunchok, T., Nabel, C. S., et al. (2024) · eLife · doi:10.7554/elife.95652 · Cited by 22

Fermentative Production of l-2-Hydroxyglutarate by Engineered Corynebacterium glutamicum via Pathway Extension of l-Lysine Biosynthesis

Prell, C., Burgardt, A., Meyer, F., & Wendisch, V. F. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.630476 · Cited by 18

Metabolomics in renal cell carcinoma: From biomarker identification to pathomechanism insights

Chen, Y., Hu, H.-H., Wang, Y., Liu, J., Liu, H., Liu, J., & Zhao, Y. (2020) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2020.108623 · Cited by 18

Metabolic reprogramming in cancer: mechanistic insights from Drosophila

Wong, K. K. L., & Verheyen, E. M. (2021) · Disease Models & Mechanisms · doi:10.1242/dmm.048934 · Cited by 20

Renal Carcinogenesis, Tumor Heterogeneity, and Reactive Oxygen Species: Tactics Evolved

Shanmugasundaram, K., & Block, K. L. (2016) · Antioxidants and Redox Signaling · doi:10.1089/ars.2015.6569 · Cited by 19

TNFAIP8 drives metabolic reprogramming to promote prostate cancer cell proliferation

Niture, S. K., Lin, M., Odera, J. O., Moore, J. T., Zhe, H., Chen, X. L., Suy, S., Collins, S. P., & Kumar, D. (2020) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2020.105885 · Cited by 16

Reprogramming Carbohydrate Metabolism in Cancer and Its Role in Regulating the Tumor Microenvironment

Adhikari, S., Guha, D., Mohan, C., Mukherjee, S., Tyler, J. K., & Das, C. (2022) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-3-031-07634-3_1 · Cited by 19

Compartmentation of Metabolites in Regulating Epigenomes of Cancer

Zhao, Z., Wang, L., & Di, L. (2016) · Molecular Medicine · doi:10.2119/molmed.2016.00051 · Cited by 18

Identification of metabolism-associated genes and pathways involved in different stages of clear cell renal cell carcinoma

Li, H., Li, W., Dai, S., Guo, Y., Zheng, J., Liu, J., Wang, Q., Chen, B., Li, G., & Huang, J. (2017) · Oncology Letters · doi:10.3892/ol.2017.7567 · Cited by 17

An olive oil phenolic is a new chemotype of mutant isocitrate dehydrogenase 1 (IDH1) inhibitors

Verdura, S., Cuyàs, E., Lozano‐Sánchez, J., Bastidas-Velez, C., Llorach-Parés, L., Fernández‐Arroyo, S., Hernández‐Aguilera, A., Joven, J., Nonell‐Canals, A., Bosch‐Barrera, J., et al. (2018) · Carcinogenesis · doi:10.1093/carcin/bgy159 · Cited by 17

Nrf2 sensitizes ferroptosis through L-2-hydroxyglutarate-mediated chromatin modifications in sickle cell disease

Xi, C., Pang, J., Zhi, W., Chang, C., Siddaramappa, U., Shi, H., Horuzsko, A., Pace, B. S., & Zhu, X. (2023) · Blood · doi:10.1182/blood.2022018159 · Cited by 16

Another small molecule in the oncometabolite mix: L-2-Hydroxyglutarate in kidney cancer

Shim, E., & Sudarshan, S. (2015) · Oncoscience · doi:10.18632/oncoscience.165 · Cited by 16

Involvement of an Orphan Transporter, SLC22A18, in Cell Growth and Drug Resistance of Human Breast Cancer MCF7 Cells

Ito, S., Fujino, Y., Ogata, S., Hirayama‐Kurogi, M., & Ohtsuki, S. (2018) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2018.08.011 · Cited by 16

Teleological role of L-2-hydroxyglutarate dehydrogenase in the kidney

Brinkley, G. J., Nam, H., Shim, E., Kirkman, R. L., Kundu, A., Karki, S., Heidarian, Y., Tennessen, J. M., Liu, J., Locasale, J. W., et al. (2020) · Disease Models & Mechanisms · doi:10.1242/dmm.045898 · Cited by 16

Proteomics-based target identification of natural products affecting cancer metabolism

Muroi, M., & Osada, H. (2021) · The Journal of Antibiotics · doi:10.1038/s41429-021-00437-y · Cited by 16

Epigenetic Heterogeneity of B-Cell Lymphoma: Chromatin Modifiers

Hopp, L., Nersisyan, L., Loeffler‐Wirth, H., Arakelyan, A., & Binder, H. (2015) · Genes · doi:10.3390/genes6041076 · Cited by 16

ADHFE1 is a MYC-linked oncogene that induces metabolic reprogramming and cellular de-differentiation in breast cancer

Mishra, P., Tang, W., & Ambs, S. (2018) · Molecular & Cellular Oncology · doi:10.1080/23723556.2018.1432260 · Cited by 16

Transcriptional regulation of metabolism in disease: From transcription factors to epigenetics

Hawkins, L. J., Al-attar, R., & Storey, K. B. (2018) · PeerJ · doi:10.7717/peerj.5062 · Cited by 17

Isocitrate Dehydrogenase Mutations in Cancer: Mechanisms of Transformation and Metabolic LiabilityPreprint

Gunn, K., & Losman, J.-A. (2024) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041537 · Cited by 16

Deciphering the multifaceted roles and clinical implications of 2-hydroxyglutarate in cancer

Hao, J., Huang, Z., Zhang, S., Song, K., Wang, J., Gao, C., Fang, Z., & Zhang, N. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107437 · Cited by 15

2-hydroxyglutarate rides the cancer-immunity cycle

Foskolou, I. P., Bunse, L., & den Bossche, J. V. (2023) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2023.102976 · Cited by 17

Investigation of Plasma Metabolic and Lipidomic Characteristics of a Chinese Cohort and a Pilot Study of Renal Cell Carcinoma Biomarker

Liu, X., Zhang, M., Liu, X., Sun, H., Guo, Z., Tang, X., Wang, Z., Li, J., He, L., Zhang, W., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01507 · Cited by 15

The Enzymology of 2-Hydroxyglutarate, 2-Hydroxyglutaramate and 2-Hydroxysuccinamate and Their Relationship to Oncometabolites

Hariharan, V., Denton, T. T., Paraszcszak, S., McEvoy, K., Jeitner, T. M., Krasnikov, B. F., & Cooper, A. J. L. (2017) · Biology · doi:10.3390/biology6020024 · Cited by 15

HIF1α is not a target of 14q deletion in clear cell renal cancer

Shenoy, N. (2020) · Scientific Reports · doi:10.1038/s41598-020-74631-7 · Cited by 14

DNA damage-induced senescence is associated with metabolomic reprogramming in breast cancer cells

George, N., Joshi, M. B., & Satyamoorthy, K. (2023) · Biochimie · doi:10.1016/j.biochi.2023.09.021 · Cited by 16

Structure and biochemical characterization of l-2-hydroxyglutarate dehydrogenase and its role in the pathogenesis of l-2-hydroxyglutaric aciduria

Yang, J., Chen, X., Jin, S., & Ding, J. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.105491 · Cited by 14

A review on exploring the impact of graphene oxide-based nanomaterials on structures and bioactivity of proteins

Sharma, N., Yadav, D., Hassan, M. I., Srivastava, C. M., & Majumder, S. (2024) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2024.124980 · Cited by 17

2‐Hydoxyglutarate: D/Riving Pathology in gLiomaS

Wahl, D. R., & Venneti, S. (2015) · Brain Pathology · doi:10.1111/bpa.12309 · Cited by 14

Background Levels of Neomorphic 2-hydroxyglutarate Facilitate Proliferation of Primary Fibroblasts

Dvořák, A., Zelenka, J., Smolková, K., Vı́tek, L., & Ježek, P. (2017) · Physiological Research · doi:10.33549/physiolres.933249 · Cited by 14

Degradation of D-2-hydroxyglutarate in the presence of isocitrate dehydrogenase mutations

Berger, R. S., Ellmann, L., Reinders, J., Kreutz, M. P., Stempfl, T., Oefner, P. J., & Dettmer, K. (2019) · Scientific Reports · doi:10.1038/s41598-019-43891-3 · Cited by 14

Emerging roles of metabolic biomarkers in renal cell carcinoma: from molecular mechanisms to clinical implications

Yang, J., Miao, D., Li, X., Zhao, C., Tan, D., Wu, S., Lu, F., Shi, J., Lv, Q., Ruan, H., et al. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1664292 · Cited by 15

D-2-hydroxyglutarate supports a tolerogenic phenotype with lowered major histocompatibility class II expression in non-malignant dendritic cells and acute myeloid leukemia cells

Hammon, K., Renner, K., Althammer, M., Voll, F., Babl, N., Decking, S.-M., Siska, P. J., Matos, C., Cárdenas-Conejo, Z. E., Mendes, K., et al. (2024) · Haematologica · doi:10.3324/haematol.2023.283597 · Cited by 16

Rapid chiral discrimination of oncometabolite dl ‐2‐hydroxyglutaric acid using derivatization and field asymmetric waveform ion mobility spectrometry/mass spectrometry

Fukui, S., Sugiyama, E., Mizuno, H., Sakane, I., Asakawa, D., Saikusa, K., Nishiya, Y., Amano, Y., Takahara, K., Higo, D., et al. (2021) · Journal of Separation Science · doi:10.1002/jssc.202100350 · Cited by 13

Metabolic Reprogramming and Reconstruction: Integration of Experimental and Computational Studies to Set the Path Forward in ADPKD

Pagliarini, R., & Podrini, C. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.740087 · Cited by 14

Quantitative Profiling of Oncometabolites in Frozen and Formalin-Fixed Paraffin-Embedded Tissue Specimens by Liquid Chromatography Coupled with Tandem Mass Spectrometry

Bao, X., Wu, J., Shuch, B. M., LoRusso, P. M., Bindra, R. S., & Li, J. (2019) · Scientific Reports · doi:10.1038/s41598-019-47669-5 · Cited by 13

Genomic Landscape of Chinese Clear Cell Renal Cell Carcinoma Patients With Venous Tumor Thrombus Identifies Chromosome 9 and 14 Deletions and Related Immunosuppressive Microenvironment

Niu, S., Liu, K., Xu, Y., Peng, C. Y., Yao, Y., Huang, Q., Wu, S., Cui, B., Huang, Y., Ma, X., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.646338 · Cited by 13

Discordant intracellular and plasma D-2-hydroxyglutarate levels in a patient with IDH2 mutated angioimmunoblastic T-cell lymphoma.

Churchill, H. R. O., Naina, H. V. K., Boriack, R. L., Rakheja, D., & Chen, W. (2015) · PubMed Central · Cited by 13

The oncometabolite L-2-hydroxyglutarate is a common product of dipteran larval development

Mahmoudzadeh, N. H., Fitt, A. J., Schwab, D. B., Martenis, W. E., Nease, L. M., Owings, C. G., Brinkley, G. J., Li, H., Karty, J. A., Sudarshan, S., et al. (2020) · Insect Biochemistry and Molecular Biology · doi:10.1016/j.ibmb.2020.103493 · Cited by 12

An IDH-independent mechanism of DNA hypermethylation upon VHL inactivation in cancer

Artemov, A. V., Zhenilo, S. V., Kaplun, D., Starshin, A., Sokolov, A., Mazur, A. M., Szpotan, J., Gawroński, M., Modrzejewska, M., Gackowski, D., et al. (2021) · Epigenetics · doi:10.1080/15592294.2021.1971372 · Cited by 12

Renal oncometabolite L-2-hydroxyglutarate imposes a block in kidney tubulogenesis: Evidence for an epigenetic basis for the L-2HG-induced impairment of differentiation

Taub, M. L., Mahmoudzadeh, N. H., Tennessen, J. M., & Sudarshan, S. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.932286 · Cited by 12

Rotenone Stereospecifically Increases (S)-2-Hydroxyglutarate in SH-SY5Y Neuronal Cells

Worth, A. J., Gillespie, K. P., Mesaros, C., Guo, L., Basu, S. S., Snyder, N. W., & Blair, I. A. (2015) · Chemical Research in Toxicology · doi:10.1021/tx500535c · Cited by 12

Computational analysis of receptor tyrosine kinase inhibitors and cancer metabolism: implications for treatment and discovery of potential therapeutic signatures

Li, J., Halfter, K., Zhang, M., Saad, C., Xu, K. L., Bauer, B., Huang, Y., Shi, L., & Mansmann, U. (2019) · BMC Cancer · doi:10.1186/s12885-019-5804-0 · Cited by 12

Urine metabolomics analysis of sleep quality in deep-underground miners: A pilot study

Wen, Q., Zhou, J., Sun, X., Ma, T., Liu, Y., Xie, Y., Wang, L., Cheng, J., Wen, J., Wu, J., et al. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.969113 · Cited by 11

Blockage of L2HGDH-mediated S-2HG catabolism orchestrates macrophage polarization to elicit antitumor immunity

Feng, S., Wang, D., Jin, Y., Huang, S., Liang, T., Sun, W., Du, X., Zhuo, L., Shan, C., Zhang, W., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114300 · Cited by 10

The epigenetic–metabolic interplay in gliomagenesis

Phasaludeen, B., Emerald, B. S., & Ansari, S. A. (2022) · Open Biology · doi:10.1098/rsob.210350 · Cited by 10

Beyond Isocitrate Dehydrogenase Mutations: Emerging Mechanisms for the Accumulation of the Oncometabolite 2-Hydroxyglutarate

Peng, S., Chen, H., Chen, L., Yang, G., Liu, J., Cheng, X., & Tang, Y. (2022) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.1c00254 · Cited by 10

Molecular signature of renal cell carcinoma by means of a multiplatform metabolomics analysis

Kordalewska, M., Wawrzyniak, R., Jacyna, J., Godzień, J., López‐Gonzálvez, Á., Raczak‐Gutknecht, J., Markuszewski, M., Gutknecht, P. G., Matuszewski, M., Siebert, J., et al. (2022) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2022.101318 · Cited by 10

Measurement of Oncometabolites d-2-Hydroxyglutaric Acid and l-2-Hydroxyglutaric Acid

Jones, P. M., Boriack, R. L., Struys, E. A., & Rakheja, D. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7142-8_14 · Cited by 10

l-2-Hydroxyglutarate remodeling of the epigenome and epitranscriptome creates a metabolic vulnerability in kidney cancer models

Kundu, A., Brinkley, G. J., Nam, H., Karki, S., Kirkman, R. L., Pandit, M., Shim, E., Widden, H., Liu, J., Heidarian, Y., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci171294 · Cited by 9

Metabolic Responses to Redox Stress in Vascular Cells

Xiao, W., Lee, L. Y.-H., & Loscalzo, J. (2024) · Antioxidants and Redox Signaling · doi:10.1089/ars.2023.0476 · Cited by 9

Tricarboxylic Acid Cycle Relationships with Non-Metabolic Processes: A Short Story with DNA Repair and Its Consequences on Cancer Therapy Resistance

Álvarez-González, E., & Sierra, L. M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25169054 · Cited by 10

The 2-oxoglutarate analog 3-oxoglutarate decreases normoxic hypoxia-inducible factor-1α in cancer cells, induces cell death, and reduces tumor xenograft growth

Koivunen, P., Fell, S. M., Lu, W., Rabinowitz, J. D., Kung, A. L., & Schlisio, S. (2016) · Hypoxia · doi:10.2147/hp.s96366 · Cited by 10

A Phase I Pharmacologic Study of Necitumumab (IMC-11F8), a Fully Human IgG1 Monoclonal Antibody

Bader, A. G., Brown, D., Winkler, M., Shim, E., Livi, C. B., Rakheja, D., Tan, J. C., Benson, D. G., Parekh, V., Kho, E.-Y., et al. (2014)

Abstract LB-131: Elevated (L) -2-hydroxyglutarate promotes loss of 5-hydroxymethylcytosine in clear cell renal cancer

Shim, E., Livi, C. B., Knight, J., Holmes, R. P., Rakheja, D., Velu, S. E., Kho, E.-Y., Chenna, B., Rea, S. L., Benson, D. G., et al. (2014) · Cancer Research · doi:10.1158/1538-7445.am2014-lb-131

Another small molecule in the oncometabolite mix: L-2-Hydroxyglutarate in kidney cancer

Shim, E., & Sudarshan, S. (2015) · Oncoscience · doi:10.18632/oncoscience.165 · Cited by 16

Oncometabolite L-2-Hydroxyglutarate Promotes Oncogenesis of Renal Cell Carcinomas by Down-Regulating Differentiation

Taub, M. L. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.108992 · Cited by 1

Abstract 5482: L-2HG/ L2HGDH axis as therapeutic target for kidney cancer

Shelar, S. B., Shim, E., Brinkley, G. J., Kundu, A., Nam, H., Carobbio, F., Poston, T. L., Tan, J. C., Benson, D. G., Rakheja, D., et al. (2018) · Cancer Research · doi:10.1158/1538-7445.am2018-5482